Glaxosmithkline Stock News

The BA.2 sub-variant of Omicron is estimated to make up nearly 12% of all COVID-19 variants circulating in the U.S., the latest genomic surveillance data from the Centers for…

This pharmaceutical company is growing revenue and profits from drugs it doesn't market or sell.

Sanofi with ticker code (SNY) have now 4 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The target price ranges between 68.5 and 58 calculating the average target price we see 63.63. Given that the stocks previous close was at 50.18 this indicates there is a potential upside of 26.8%. The 50 day MA is 51.58 while the 200 day moving average is 50.94. The market capitalisation for the company is $121,066m. You can visit the company''s website by visiting: https://www.sanofi.com [stock_market_widget type="chart" template="basic" color="green" assets=SNY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $153,516m based on the market concensus. Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.

Vir Bio has a COVID blockbuster in Xevudy, and the stock is super-cheap right now.

Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca. Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca.

Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co. Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co.

GlaxoSmithKline (GSK) closed the most recent trading day at $41.45, moving -1.38% from the previous trading session.

Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.

Microsoft, SpaceX, Airbnb and GlaxoSmithKline are among the businesses helping the country fend off cyberattacks, supplying painkillers and providing internet service during Russia’s assault.

Baird has upgraded Vir Biotechnology <>, the partner of GlaxoSmithKline (GSK) in the development of COVID-19 therapy sotrovimab, to Neutral from Underperform, citing the recent…

Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.

Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. , Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co. Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. , Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co.

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals. Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.

GlaxoSmithKline plc with ticker (LON:GSK) now has a potential downside of -2.9% according to Deutsche. [stock_market_widget type="chart" template="basic" color="green" assets="GSK.L" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] Deutsche set a target price of 1,500 GBX for the company, which when compared to the GlaxoSmithKline plc share price of 1,544 GBX at opening today (03/03/2022) indicates a potential downside of -2.9%. Trading has ranged between 1,199 (52 week low) and 1,737 (52 week high) with an average of 9,462,814 shares exchanging hands daily. The market capitalisation at the time of writing is £78,236,450,100. GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology.